Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 3Active not recruiting 1

Sponsor Class

OTHER 15NIH 6INDUSTRY 4OTHER_GOV 1

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Gastrointestinal 86Genitourinary 39Tumor-Agnostic 11Thoracic 7Dermatologic 5Head & Neck 4Breast 3Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1CNS 1

Conditions

Thyroid Neoplasms 4Carcinoma, Medullary 1

Interventions

pembrolizumab 166Cisplatin 112Cetuximab 76Nivolumab 52Carboplatin 51Fluorouracil 48Paclitaxel 42Docetaxel 37Gemcitabine 30Radiotherapy 28Capecitabine 19Cyclophosphamide 18durvalumab 17Injections 17lenvatinib 16atezolizumab 16cemiplimab 15spartalizumab 13fludarabine 13avelumab 12Ipilimumab 12Pemetrexed 11130-nm albumin-bound paclitaxel 11Oxaliplatin 10Gefitinib 10tremelimumab 9Drug Therapy 9tislelizumab 8epacadostat 8budigalimab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Sorafenib × Head & Neck × Clear all
NCT02185560 2026-04-14

JPMS-DTC

Bayer

Active not recruiting
453 enrolled
Head & Neck

Thyroid Neoplasms

NCT02303444 2023-06-08

RIFTOS MKI

Bayer

Completed
667 enrolled
Head & Neck

Thyroid Neoplasms

NCT00984282 2018-09-13

Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer

Bayer

Phase 3 Completed
417 enrolled 22 charts
Head & Neck

Thyroid Neoplasms

NCT02114658 2017-08-03

Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients

Bayer

Phase 2 Completed
18 enrolled
Head & Neck

Thyroid Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡